Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant

Uložené v:

Podrobná bibliografia
Vydané v:	Haematologica (Roma) Ročník 108; číslo 2; s. 615 - 620
Hlavní autori:	Chen, George, Herr, Megan, Nowak, Jan, Ho, Christine, Almyroudis, Nikolaos, Attwood, Kristopher, Bonnewell, John, Walsh, Marissa, Segal, Brahm, Ross, Maureen, McCarthy, Philip, Hahn, Theresa
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Italy Fondazione Ferrata Storti 01.02.2023 Ferrata Storti Foundation
Predmet:	Antigens, CD19 Cytomegalovirus Humans Immunotherapy, Adoptive - adverse effects Letter to the Editor Lymphoma, B-Cell - therapy Receptors, Antigen, T-Cell T-Lymphocytes
ISSN:	0390-6078, 1592-8721, 1592-8721
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Bibliografia:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Correspondence-1 content type line 23 Disclosures BS receives research funding from NextCure and Apellis and is on the advisory board for NextCure. GLC receives clinical research funding from Actinium, AlloVir, and Takeda. PLM receives consultancy fees / honoraria / research funding from Bluebird Bio, BMS/Celgene/Juno, Fate Therapeutics, Hikma, Janssen, Karyopharm, Magenta Therapeutics, Novartis, Oncopeptides, Partner Therapeutics, Sanofi, Starton Therapeutics, and Takeda. The remaining authors have no conflicts of interest to disclose. Contributions GLC wrote the manuscript. GLC and MH designed research. GLC, MH, JN, NA, NW.JB,CH, MR,BS, PLM, and TH provided data. GLC, MH, BS, PLM, and TH analyzed data. All authors read and commented on the manuscript. Please address requests for data to GC. Data-sharing statement
ISSN:	0390-6078 1592-8721 1592-8721
DOI:	10.3324/haematol.2022.281719